---
title: Markel Group Inc. (MKL)
layout: default
nav_order: 555
---

# Markel Group Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $17.22 B

Markel is a specialty insurance company with operations in insurance, reinsurance, investments, and Markel Ventures.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=MKL+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/MKL/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat:**

{: .warning }
Markel's moat stems primarily from its specialty insurance business, giving it some pricing power in niche markets. The company benefits from a degree of customer lock-in, specifically in its excess and surplus lines business. These customer relationships, alongside experienced underwriters, allow Markel to generate underwriting profits, even during challenging times for the insurance sector. However,  the competitive advantages afforded by specialty insurance are not absolute or unassailable. The barriers to entry are lower in the insurance industry when compared to other sectors like pharmaceuticals, software, or consumer staples, partially justifying the lower moat rating.

**Management:**

{: .important }
Management receives a rating of 3/5.  While the company has a long history of responsible capital allocation and has delivered healthy returns to shareholders, there are some issues that limit a higher rating. Executive compensation, while not exorbitant by current standards, is significantly tied to stock options, potentially creating short-term incentives.  Although there have been share repurchases, they are not as consistent or substantial as some would expect from an intrinsically oriented company. Communication is generally clear, though some additional transparency regarding individual business segment performance could enhance investor understanding.  The CEO's tenure is relatively short, with just two years at the helm, which limits my ability to fully assess long-term leadership potential.  Finally, the company has faced some legal challenges in the recent past which, though resolved, raise concerns. (Information sourced from MKL annual reports and conference calls from 2019-2023)

**Catalyst:**

{: .note }
Markel Ventures, the company's non-insurance business segment, represents a potential catalyst. The segment has a diverse set of businesses with solid growth potential. As the company continues to make accretive acquisitions and improve operating efficiency in Markel Ventures, the segment's value may increase, which may lead to a higher market value for Markel overall. However, this catalyst is not immediate or certain, hence the modest rating of 2/5.

**Business:**

* **Insurance:** Markel's core business is specialty insurance where it underwrites excess and surplus lines, admitted insurance, and reinsurance in niche markets. The company’s competitive advantage in this segment stems from its focus on specialty insurance. Specialty insurance provides coverage for unique risks that are often difficult to place in the standard market. This makes it a less competitive market than other areas of the insurance industry.
* **Reinsurance:**  Markel’s reinsurance operations provide coverage for catastrophic events such as hurricanes and earthquakes. This business, as of today, seems secondary relative to Markel’s primary insurance business, though it does help increase scale and diversity of risk.
* **Investments:** Markel invests a substantial portion of its float (premiums collected but not yet paid out as claims) in equities. This investment portfolio is an important element of value creation for Markel, providing a cushion against losses in its insurance operations.
* **Markel Ventures:**  This segment includes a diverse set of businesses ranging from manufacturing to services. Although relatively small compared to Markel’s insurance operations, it has shown strong growth in recent years, which may be a source of value creation. 

**Financials:**

Markel's financials, analyzed from 2019 to 2023, show a strong insurance business with consistent underwriting profits.  Markel Ventures has also demonstrated strong growth, although its profitability has fluctuated.  The investment portfolio has delivered healthy returns, although recent market volatility has caused some mark-to-market losses. A key concern for the company is related to rising interest rates, which could potentially compress margins in its insurance operations and reduce the value of its investment portfolio, justifying the slightly pessimistic view adopted in the valuation. (Information derived from MKL's 10K and 10Q reports from 2019-2023)

**Valuation:**

I employed a discounted cash flow (DCF) model to value Markel, recognizing it as the most reliable method for valuing any company. I broke down the valuation into operating assets, non-operating assets, and financial claims.

**Assumptions:**

* **Revenue Growth:** 5% (pessimistic view given potential macroeconomic headwinds)
* **Operating Margin:**  10% (based on historical performance and industry averages)
* **Sales/Capital Ratio:** 1.2 (based on historical performance)
* **Reinvestment Rate:** 40% (conservative approach)
* **Tax Rate:** 25% (based on effective tax rate)
* **Cost of Capital:** 8.5% (based on current risk-free rate, equity risk premium, and company beta)
* **Terminal Growth Rate:** 3% (conservative view given mature industry)

**Calculations:**

1. **Forecast financials:** I projected financial statements (income statement, balance sheet, and cash flow statement) for the next 10 years using the above assumptions.
2. **Calculate free cash flow (FCF):**  FCF was calculated as Net Operating Profit After Taxes (NOPAT) minus Net Investment.
3. **Calculate continuing value:**  I used a perpetuity growth model to estimate Markel's continuing value after 10 years.

CV = FCF<sub>11</sub> / (Cost of Capital - Terminal Growth Rate)

4. **Discount cash flows:**  I discounted the projected FCFs and continuing value back to today's value using the cost of capital.
5. **Value non-operating assets:**  These were valued using market values and adjusted for taxes.
6. **Value debt and other claims:** Debt was valued using market values, and other claims (leases, minority interests, and employee options) were valued based on their financial characteristics.
7. **Calculate equity value:** Equity value was calculated as the sum of the present value of operating assets, non-operating assets, and the value of other financial assets, minus the present value of debt and other claims. 

The resulting equity value was $17.22 billion. Dividing this by the number of shares outstanding resulted in an estimated fair value per share.

**Sensitivity Analysis and Scenarios:**

To test the robustness of the base case, I performed sensitivity analysis on key assumptions such as revenue growth, operating margins, and the cost of capital.  I also developed alternative scenarios such as a macroeconomic downturn and a faster growth scenario for Markel Ventures. The results of this analysis suggested that Markel's valuation is relatively sensitive to changes in these assumptions.  However, even under pessimistic scenarios, the company's fair value remains above its current market price, suggesting that the stock is undervalued. 

**Conclusion:**

Markel, with its established specialty insurance business, possesses a moderate moat. Although there are concerns about management and potential headwinds, the company's strong fundamentals and current valuation suggest that the stock is undervalued.  Markel Ventures offers a long-term growth catalyst, though not a significant near-term driver of returns.  Given the recent market volatility and the possibility of a prolonged economic slowdown, a pessimistic outlook is warranted.  However, if the market provides us with a margin of safety by offering MKL at an attractive price, an investment may be considered, especially if you are an intrinsic investor with a long time horizon.